The growing TIGIT pipeline: Data Byte

At least 17 therapeutic candidates targeting TIGIT are in preclinical and clinical testing for cancer, according to BioCentury’s BCIQ database.

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) is in the lead, with anti-TIGIT mAb tiragolumab, which was the standout performer among next-generation checkpoint inhibitors at last year’s American Society of Clinical Oncology (ASCO) conference, and the first to finally deliver in the clinic what next-generation checkpoints have promised preclinically. ...